Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Physician Survey of Timing of Adjuvant Endocrine Therapy Relative to Radiotherapy in Early Stage Breast Cancer Patients.

McGee SF, Vandermeer L, Mazzarello S, Sienkiewicz M, Stober C, Hutton B, Fergusson D, Hilton J, Caudrelier JM, Blanchette P, Clemons M.

Clin Breast Cancer. 2018 Sep 4. pii: S1526-8209(18)30204-0. doi: 10.1016/j.clbc.2018.08.012. [Epub ahead of print]

PMID:
30318304
2.

Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic Review.

Fernandes R, Mazzarello S, Stober C, Ibrahim MFK, Dudani S, Perdrizet K, Majeed H, Vandermeer L, Shorr R, Hutton B, Fergusson D, Gyawali B, Clemons M.

J Glob Oncol. 2018 Sep;(4):1-8. doi: 10.1200/JGO.2016.008540. Epub 2017 Apr 21.

3.

Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC).

Clemons M, Mazzarello S, Hilton J, Joy A, Price-Hiller J, Zhu X, Verma S, Kehoe A, Ibrahim MF, Sienkiewicz M, Stober C, Vandermeer L, Hutton B, Mallick R, Fergusson D.

Support Care Cancer. 2018 Aug 11. doi: 10.1007/s00520-018-4408-6. [Epub ahead of print]

PMID:
30099602
4.

Randomised feasibility trial to compare three standard of care chemotherapy regimens for early stage triple-negative breast cancer (REaCT-TNBC trial).

Hilton J, Stober C, Mazzarello S, Vandermeer L, Fergusson D, Hutton B, Clemons M.

PLoS One. 2018 Jul 24;13(7):e0199297. doi: 10.1371/journal.pone.0199297. eCollection 2018.

5.

Optimal sequence of adjuvant endocrine and radiation therapy in early-stage breast cancer - A systematic review.

McGee SF, Mazzarello S, Caudrelier JM, Lima MAG, Hutton B, Sienkiewicz M, Stober C, Fernandes R, Ibrahim MFK, Vandermeer L, Hilton J, Shorr R, Fergusson D, Clemons M.

Cancer Treat Rev. 2018 Sep;69:132-142. doi: 10.1016/j.ctrv.2018.06.015. Epub 2018 Jun 28. Review.

PMID:
30014951
6.

Optimal vascular access strategies for patients receiving chemotherapy for early-stage breast cancer: a systematic review.

Robinson A, Souied O, Bota AB, Levasseur N, Stober C, Hilton J, Kamel D, Hutton B, Vandermeer L, Mazzarello S, Joy AA, Fergusson D, McDiarmid S, McInnes M, Shorr R, Clemons M.

Breast Cancer Res Treat. 2018 Oct;171(3):607-620. doi: 10.1007/s10549-018-4868-x. Epub 2018 Jul 4. Review.

PMID:
29974358
7.

Taxane acute pain syndrome (TAPS) in patients receiving chemotherapy for breast or prostate cancer: a prospective multi-center study.

Fernandes R, Mazzarello S, Joy AA, Pond GR, Hilton J, Ibrahim MFK, Canil C, Ong M, Stober C, Vandermeer L, Hutton B, da Costa M, Damaraju S, Clemons M.

Support Care Cancer. 2018 Sep;26(9):3073-3081. doi: 10.1007/s00520-018-4161-x. Epub 2018 Mar 21.

PMID:
29564623
8.

Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients.

Hilton J, Vandermeer L, Sienkiewicz M, Mazzarello S, Hutton B, Stober C, Fergusson D, Blanchette P, Joy AA, Brianne Bota A, Clemons M.

Support Care Cancer. 2018 Jul;26(7):2323-2331. doi: 10.1007/s00520-018-4074-8. Epub 2018 Feb 6.

PMID:
29411131
9.

A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer.

Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M.

Breast Cancer Res Treat. 2018 Apr;168(2):371-379. doi: 10.1007/s10549-017-4604-y. Epub 2017 Dec 6.

PMID:
29214415
10.

Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer.

Hilton JF, Clemons M, Pond G, Zhao H, Mazzarello S, Vandermeer L, Addison CL.

J Bone Oncol. 2017 Nov 8;10:6-13. doi: 10.1016/j.jbo.2017.11.001. eCollection 2018 Mar.

11.

A cost-utility analysis of risk model-guided versus physician's choice antiemetic prophylaxis in patients receiving chemotherapy for early-stage breast cancer: a net benefit regression approach.

Thavorn K, Coyle D, Hoch JS, Vandermeer L, Mazzarello S, Wang Z, Dranitsaris G, Fergusson D, Clemons M.

Support Care Cancer. 2017 Aug;25(8):2505-2513. doi: 10.1007/s00520-017-3658-z. Epub 2017 Mar 9.

PMID:
28281050
12.

Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients.

Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, Freedman O, Vandermeer L, Ibrahim M, Fergusson D, Hilton J.

Support Care Cancer. 2017 Jun;25(6):1881-1886. doi: 10.1007/s00520-017-3580-4. Epub 2017 Jan 27.

PMID:
28127659
13.

Strategies for obtaining bone biopsy specimens from breast cancer patients - Past experience and future directions.

Ibrahim MF, Hilton J, Addison C, Robertson S, Werier J, Mazzarello S, Vandermeer L, Jacobs C, Clemons M.

J Bone Oncol. 2016 Jul 7;5(4):180-184. doi: 10.1016/j.jbo.2016.07.001. eCollection 2016 Nov.

14.

A phase 2 trial exploring the clinical and correlative effects of combining doxycycline with bone-targeted therapy in patients with metastatic breast cancer.

Addison CL, Simos D, Wang Z, Pond G, Smith S, Robertson S, Mazzarello S, Singh G, Vandermeer L, Fernandes R, Iyengar A, Verma S, Clemons M.

J Bone Oncol. 2016 Jul 1;5(4):173-179. doi: 10.1016/j.jbo.2016.06.003. eCollection 2016 Nov.

15.

Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.

Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, Majeed H, Perdrizet K, Shorr R, Hutton B, Fergusson D, Clemons M.

Breast Cancer Res Treat. 2017 Jan;161(1):1-10. doi: 10.1007/s10549-016-4028-0. Epub 2016 Oct 25. Review.

PMID:
27783280
16.

Novel Methodology for Comparing Standard-of-Care Interventions in Patients With Cancer.

Hilton J, Mazzarello S, Fergusson D, Joy AA, Robinson A, Arnaout A, Hutton B, Vandermeer L, Clemons M.

J Oncol Pract. 2016 Dec;12(12):e1016-e1024. Epub 2016 Sep 30.

PMID:
27650842
17.

Optimal Management of Leptomeningeal Carcinomatosis in Breast Cancer Patients-A Systematic Review.

Dudani S, Mazzarello S, Hilton J, Hutton B, Vandermeer L, Fernandes R, Ibrahim MF, Smith S, Majeed H, Al-Baimani K, Caudrelier JM, Shorr R, Clemons M.

Clin Breast Cancer. 2016 Dec;16(6):456-470. doi: 10.1016/j.clbc.2016.07.014. Epub 2016 Jul 28. Review.

PMID:
27553811
18.

Choice of study endpoint significantly impacts the results of breast cancer trials evaluating chemotherapy-induced nausea and vomiting.

Ng T, Mazzarello S, Wang Z, Hutton B, Dranitsaris G, Vandermeer L, Smith S, Clemons M.

Breast Cancer Res Treat. 2016 Jan;155(2):337-44. doi: 10.1007/s10549-015-3669-8. Epub 2016 Jan 5.

PMID:
26732944
19.

A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.

Jacobs C, Kuchuk I, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Dranitsaris G, Dent S, Gertler S, Verma S, Song X, Simos S, Cella D, Clemons M.

Breast Cancer Res Treat. 2016 Jan;155(1):77-84. doi: 10.1007/s10549-015-3646-2. Epub 2015 Dec 7.

PMID:
26643085
20.

Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.

Clemons M, Bouganim N, Smith S, Mazzarello S, Vandermeer L, Segal R, Dent S, Gertler S, Song X, Wheatley-Price P, Dranitsaris G.

JAMA Oncol. 2016 Feb;2(2):225-31. doi: 10.1001/jamaoncol.2015.3730.

PMID:
26562292
21.

Measuring the impact of guideline-based antiemetic therapy on nausea and vomiting control in breast cancer patients with multiple risk factors.

Dranitsaris G, Mazzarello S, Smith S, Vandermeer L, Bouganim N, Clemons M.

Support Care Cancer. 2016 Apr;24(4):1563-9. doi: 10.1007/s00520-015-2944-x. Epub 2015 Sep 17.

PMID:
26381427
22.

Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis.

Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, Hutton B, Clemons M.

Ann Oncol. 2015 Nov;26(11):2205-13. doi: 10.1093/annonc/mdv284. Epub 2015 Jun 28. Review.

PMID:
26122727
23.

Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases.

Addison CL, Pond GR, Zhao H, Mazzarello S, Vandermeer L, Goldstein R, Amir E, Clemons M.

Springerplus. 2014 Oct 1;3:577. doi: 10.1186/2193-1801-3-577. eCollection 2014.

24.

A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.

Addison CL, Bouganim N, Hilton J, Vandermeer L, Dent S, Amir E, Hopkins S, Kuchuk I, Segal R, Song X, Gertler S, Mazzarello S, Dranitsaris G, Ooi D, Pond G, Clemons M.

Breast Cancer Res Treat. 2014 Apr;144(3):615-24. doi: 10.1007/s10549-014-2906-x. Epub 2014 Mar 18.

25.

Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression.

Khalaf D, Hilton JF, Clemons M, Azoulay L, Yin H, Vandermeer L, Dent S, Hopkins S, Bouganim N.

Oncol Lett. 2014 Mar;7(3):866-870. Epub 2014 Jan 7.

26.

Use of conjoint analysis to assess breast cancer patient preferences for chemotherapy side effects.

Beusterien K, Grinspan J, Kuchuk I, Mazzarello S, Dent S, Gertler S, Bouganim N, Vandermeer L, Clemons M.

Oncologist. 2014 Feb;19(2):127-34. doi: 10.1634/theoncologist.2013-0359. Epub 2014 Jan 28.

27.

Preference weights for chemotherapy side effects from the perspective of women with breast cancer.

Kuchuk I, Bouganim N, Beusterien K, Grinspan J, Vandermeer L, Gertler S, Dent SF, Song X, Segal R, Mazzarello S, Crawley F, Dranitsaris G, Clemons M.

Breast Cancer Res Treat. 2013 Nov;142(1):101-7. doi: 10.1007/s10549-013-2727-3. Epub 2013 Oct 16.

PMID:
24129976
28.

Lost in transition? Thoughts on retirement--"will you still need me, will you still feed me, when i'm sixty-four?".

Clemons MJ, Vandermeer LA, Gunstone I, Jacobs C, Kaizer L, Paterson AH.

Oncologist. 2013;18(11):1235-8. doi: 10.1634/theoncologist.2013-0173. Epub 2013 Sep 16. No abstract available.

29.

Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting.

Bouganim N, Dranitsaris G, Hopkins S, Vandermeer L, Godbout L, Dent S, Wheatley-Price P, Milano C, Clemons M.

Curr Oncol. 2012 Dec;19(6):e414-21. doi: 10.3747/co.19.1074.

30.

Histomorphometric and microarchitectural analyses using the 2 mm bone marrow trephine in metastatic breast cancer patients-preliminary results.

Fralick M, Bouganim N, Kremer R, Kekre N, Robertson S, Vandermeer L, Kuchuk I, Li J, Murshed M, Clemons M.

J Bone Oncol. 2012 Dec 1;1(3):69-73. doi: 10.1016/j.jbo.2012.10.003. eCollection 2012 Dec.

31.

Detection of PIK3CA Mutations in Breast Cancer Bone Metastases.

Daneshmand M, Hanson JE, Nabavi M, Hilton JF, Vandermeer L, Kanji F, Dent SF, Clemons M, Lorimer IA.

ISRN Oncol. 2012;2012:492578. doi: 10.5402/2012/492578. Epub 2012 Aug 30.

32.

Excision of the primary tumour in patients with metastatic breast cancer: a clinical dilemma.

Samiee S, Berardi P, Bouganim N, Vandermeer L, Arnaout A, Dent S, Mirsky D, Chasen M, Caudrelier JM, Clemons M.

Curr Oncol. 2012 Aug;19(4):e270-9. doi: 10.3747/co.19.974.

33.

Use and delivery of granulocyte colony-stimulating factor in breast cancer patients receiving neoadjuvant or adjuvant chemotherapy-single-centre experience.

Zhu X, Bouganim N, Vandermeer L, Dent SF, Dranitsaris G, Clemons MJ.

Curr Oncol. 2012 Aug;19(4):e239-43. doi: 10.3747/co.19.948.

34.

Prospective validation of a prediction tool for identifying patients at high risk for chemotherapy-induced nausea and vomiting.

Dranitsaris G, Bouganim N, Milano C, Vandermeer L, Dent S, Wheatley-Price P, Laporte J, Oxborough KA, Clemons M.

J Support Oncol. 2013 Mar;11(1):14-21.

PMID:
22763232

Supplemental Content

Loading ...
Support Center